ArticleClinical kidney journal2015
A European multicentre and open-label controlled randomized trial to evaluate the efficacy of Sequential treatment with TAcrolimus-Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study.
Article in Clinical kidney journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome.The Cochrane database of systematic reviews · 2021Pooled it
- Identification of early predictors of clinical remission in primary membranous nephropathy: aClinical kidney journal · 2025Article
- Clinical study, network pharmacology, and molecular docking of Kunxian capsule in treating idiopathic membranous nephropathy.Frontiers in medicine · 2025Article
- Prognostic and therapeutic monitoring value of plasma and urinary cytokine profile in primary membranous nephropathy: the STARMEN trial cohort.Clinical kidney journal · 2024Article
- Review
- Efficacy of low or standard rituximab-based protocols and comparison to Ponticelli's regimen in membranous nephropathy.Journal of nephrology · 2021Article
- A Review of the Current Practice of Diagnosis and Treatment of Idiopathic Membranous Nephropathy in China.Medical science monitor : international medical journal of experimental and clinical research · 2021Review
- Tacrolimus Prevents TWEAK-Induced PLA2R Expression in Cultured Human Podocytes.Journal of clinical medicine · 2020Article
- Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal.Clinical kidney journal · 2019Article
- Impact of Recent Clinical Trials on Nephrology Practice: Are We in a Stagnant Era?Kidney diseases (Basel, Switzerland) · 2019Review
- Treatment of primary membranous nephropathy: where are we now?Journal of nephrology · 2018Review
- The Role of PLA2R Antibody in Treatment of Membranous Nephropathy.Kidney international reports · 2018Article
- Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy.Journal of the American Society of Nephrology : JASN · 2017Observational
- Treatment of membranous nephropathy: time for a paradigm shift.Nature reviews. Nephrology · 2017Review
- Single-dose Rituximab Therapy for Refractory Idiopathic Membranous Nephropathy: A Single-center Experience.Internal medicine (Tokyo, Japan) · 2017Article
- Recent Treatment Advances and New Trials in Adult Nephrotic Syndrome.BioMed research international · 2017Review
- CureGN-Diabetes Study: Rationale, Design, and Methods of a Prospective Observational Study of Glomerular Disease Patients with Diabetes.Glomerular diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with primary membranous nephropathy (MN) and persistent nephrotic syndrome have a high risk of progression to end-stage renal disease. The Ponticelli protocol (steroids with alkylating agents) is the most effective immunosuppressive therapy for this condition, but it has severe adverse effects. Tacrolimus and rituximab have demonstrated efficacy for remission of nephrotic syndrome in MN with a safer profile. However, the published evidence is largely based on small or short-term observational studies, historical cohorts, comparisons with conservative therapy or clinical trials without appropriate control groups, and there is no head-to-head comparison with the Ponticelli protocol.
methodsThe STARMEN randomized clinical trial will compare the efficacy of sequential tacrolimus-rituximab therapy with a modified Ponticelli protocol (steroids plus cyclophosphamide). The trial will also evaluate the role of antibodies against the M-type phospholipase A2 receptor (anti-PLA2R) and other antibodies as markers of response to treatment and long-term prognosis.
resultsThe trial has already started with 23 patients having been enrolled as of 1 April 2015, an estimated 21.7% of the estimated sample.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.